Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Closes Aquisition of Epoch for $97 Million; Epoch Ends Nasdaq Listing

NEW YORK, Dec. 17 (GenomeWeb News) - Nanogen yesterday closed its acquisition of Epoch Biosciences for $97 million. The deal was originally announced in September, and was approved by shareholders on Dec. 15.

 

Epoch Biosciences ceased trading on the Nasdaq exchange at market close on Thursday.

 

Nanogen shareholders approved the issuance of shares of common stock for the deal, and also approved an amendment to the company's certificate of incorporation increasing the number of authorized shares of Nanogen common stock to 135 million shares.

 

Epoch stockholders will receive .47 shares of Nanogen stock in exchange for each share of Epoch common stock they hold. At the completion of the merger, Nanogen will have approximately 50 million common shares outstanding.

 

The Nanogen shareholder meeting was originally held on Dec. 8, but was postponed until Dec. 15 because the number of shares represented by votes or votes by proxy was insufficient for a decision.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.